Radiolabeled hypoxic cell sensitizers: Tracers for assessment of ischemia

doi:10.1016/0024-3205(87)90494-2

Life Sciences

Volume 41, Issue 2, 13 July 1987, Pages 199-206

https://doi.org/10.1016/0024-3205(87)90494-2 Get rights and content

Abstract

Hypoxic, non-functional, but viable, tissue may exist in heart and brain following an arterial occlusion. Identification of such tissue in vivo is crucial to the development of effective treatment strategies. It has been suggested that certain compounds capable of sensitizing hypoxic tumor cells to killing by x-rays (i.e., misonidazole) might serve as in vivo markers of hypoxic tissue in ischemic myocardium or brain if properly radiolabeled. To this end we have radiolabeled two fluorinated analogs of nitroimidazole based hypoxic cell sensitizers with the 110 minute half-lived positron-emitting fluorine-18. The ability of these tracers to quantitate the presence of hypoxic tissue has been studied in a gerbil stroke model. The in vivo uptake of one of these tracers [F-18]-fluoronormethyoxymisonidazole is dependent on the extent of tissue hypoxia, and thus, appears to have potential as a diagnostic indicator of non-functional but viable tissue when the tracer is used in conjunction with positron emission tomography.

References (80)

J.E. Moulder et al.
Int. J. Radiation Oncol. Biol. Phys.
(1984)
V.W. Pike et al.
Int. J. Appl. Radiat. Isot.
(1982)
K.A. Kennedy et al.
Biochem. Pharm.
(1980)
G.G. Miller et al.
Int. J. Radiation Oncol. Biol. Phys.
(1982)
D.C. Jette et al.
Int. J. Nucl. Med. Biol.
(1983)
J.F. Fowler et al.
Cancer Treat. Rev.
(1976)
C.J. Koch et al.
Oncology Biol. Phys.
(1984)
P.A. Jerabek et al.
Int. J. Appl. Rad. Isotop.
(1986)
S. Levine et al.
Exp. Neurol.
(1966)
K. Ohno et al.
Brain Res.
(1984)

B.R. Smith et al.

Radiation Oncology Biol. Phys.

(1984)

L. Bakay

Progr. Brain Res.

(1968)

J.D. Chapman

N. Engl. J. Med.

(1979)

J.D. Chapman et al.

Br. J. Cancer

(1981)

J.D. Chapman

Cancer

(1984)

F. Plum et al.

L.H. Gray et al.

Brit. J. Radiol.

(1953)

N.J. McNally

Brit. J. Cancer

(1975)

N.J. McNally et al.

Radiat. Res.

(1979)

S. Dische

Brit. J. Radiol.

(1979)

J.M. Henk et al.

Lancet

(1977)

R.S. Bush

Brit. J. Cancer

(1978)

S. Rockwell et al.

Cell Tissue Kinet.

(1983)

L.E. Gerweck et al.

Cancer Res

(1979)

H.R. Withers

Radiol.

(1973)

H. Suit et al.

Am. J. Roentgenol.

(1967)

S. Rockwell

Brit. J. Cancer

(1980)

B.M. Garrecht et al.

Brit. J. Radiol.

(1983)

M. Horowitz

Cancer Res.

(1983)

J.S. Rasey et al.

Rad. Res.

(1982)

R.H. Thomlinson et al.

Brit. J. Cancer

(1958)

E.J. Hall et al.

Radiol.

(1975)

G.E. Adams

Br. Med. Bull.

(1973)

S.A. Hill et al.

Brit. J. Cancer

(1977)

S. Dische et al.

Brit. J. Cancer

(1977)

G.E. Adams

J.M. Brown

radiat. Res.

(1975)

R. Uratsun

N. Engl. J. Med.

(1976)

T.H. Wasserman et al.

Cancer

(1981)

Y.C. Taylor et al.

Cancer Res.

(1978)

Cited by (34)

PET Imaging of Hypoxia
2009, PET Clinics
Hypoxia imaging has applications in functional recovery in ischemic events such as stroke and myocardial ischemia, but especially in tumors in which hypoxia can be predictive of treatment response and overall prognosis. Recently, there has been development of imaging agents using PET for non-invasive imaging of hypoxia. Many of these PET agents have come to the forefront of hypoxia imaging. Halogenated PET nitroimidazole imaging agents labeled with ¹⁸F (t_1/2 = 110 m) and ¹²⁴I (t_1/2 = 110 m) have been under investigation for the last 25 years, with radiometal agents (⁶⁴Cu-ATSM) being developed more recently. This article focuses on these PET imaging agents for hypoxia.
An approach for measuring in vivo cerebral redox states using the oxidative conversion of dihydropyridine to pyridinium ion and the metabolic trapping principle
2005, Free Radical Biology and Medicine
This study was undertaken to develop radiopharmaceuticals for measuring in vivo cerebral redox states. Based on the oxidative conversion of dihydropyridine to pyridinium ion and the metabolic trapping principle, five N-[¹⁴C]methyl-3 or 3,5-substituted 1,4-dihydropyridines with different oxidation rates were designed, synthesized, and evaluated as a prototype of radiotracers for measuring in vivo cerebral redox states. When these tracers were injected into mice, they crossed the blood–brain barrier (BBB) and became trapped in the brain depending on their oxidation rates, while the corresponding oxidized forms hardly crossed the BBB. Furthermore, a significant increase in the radioactivity trapped in the brain was observed following injection of N-[¹⁴C]methyl-3-acetyl-1,4-dihydropyridine to mice pretreated with diethylmaleate that depletes glutathione in the brain. These findings suggested that an approach based on the oxidative conversion of dihydropyridine to the pyridinium ion and the metabolic trapping principle would be useful for measuring in vivo cerebral redox states.
PET radiopharmaceuticals for metabolic imaging in oncology
2004, International Congress Series
Early detection is critical to successful treatment and long-term cure of cancer. Detection relies on a broad array of mutually supporting diagnostic modalities, including visual detection of superficial lesions, quantification of biological and metabolic markers, and noninvasive imaging. The advantage of imaging techniques over circulating markers is that imaging defines the precise location of the tumor. Of the imaging techniques available today, positron emission tomography (PET) offers the best combination of selectivity, specificity, and sensitivity when used with appropriate molecular radiopharmaceuticals. In addition, PET images can be analyzed to provide quantitative kinetic data (parametric imaging) and biochemical knowledge at physiological molecular concentrations. This information is invaluable in staging, therapy planning, and therapeutic monitoring of cancer. Bioenergetics, genomics, and proteomics present unique opportunities to study and characterize cell growth and proliferation using PET. 2-[¹⁸F]FDG, a probe of one component of cellular glycolysis, is the major PET tracer used in clinical oncology today. However, the potential contributions of PET to oncology extend well beyond 2-[¹⁸F]FDG and other F-18-labeled tracers. Chemical classes of PET radiotracers commonly used in preclinical and clinical experimental oncology include carbohydrates, fatty acids, nucleosides, oligonucleotides, nitroimidazoles, amino acids, peptides, proteins, and antibodies. Fluorine-18, C-11, and radiometals are the most frequently used radionuclides. These PET radiopharmaceuticals are useful in the assessment of tissue bioenergetics, hypoxia, proliferation, and function. The following paragraphs present an overview of hexose-based measurement of glucose metabolism as an indicator of tumor viability, and nitroimidazole-based compounds as markers of regional tissue hypoxia, using PET. Emphasis is placed on the use of [¹⁸F]-fluorodeoxyglucose (FDG) and [¹⁸F] fluoroazomycin arabinoside (FAZA) in oncology.
Positron emission tomography imaging of brain tumors
2003, Neuroimaging Clinics of North America
PET in neurology and psychiatry II
2002, Revista Espanola de Medicina Nuclear
[<sup>18</sup>F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure
2001, Applied Radiation and Isotopes
There is a great deal of clinical and experimental interest in determining tissue hypoxia using non-invasive imaging methods. We have developed EF5, 2-(2-nitro-1[H]-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide, with both invasive and non-invasive hypoxia detection in mind. EF5 and other 2-nitroimidazoles are used to detect hypoxia, because the rate of their bioreductive metabolism is inversely dependent on oxygen partial pressure. Such metabolism leads to the formation of covalent adducts within the metabolizing cells. Previously, we have described the invasive detection of these adducts by highly specific monoclonal antibodies after tissue biopsy. In this report, we demonstrate the synthesis of ¹⁸F-labeled EF5, [¹⁸F]-2-(2-nitro-1[H]-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide, in greater than 10% yield by direct fluorination of the newly synthesized precursor 2-(2-nitro-1[H]-imidazol-1-yl)-N-(2,3,3-trifluoroallyl)-acetamide by [¹⁸F]-F₂ in trifluoroacetic acid. Our objective was to optimize the electrophilic fluorination of the fluorinated alkene bond with fluorine gas, a new method of ¹⁸F-labeling of polyfluorinated molecules. Previous biodistribution studies in mice have demonstrated uniform access of EF5 to all tissues with bioelimination dominated by renal excretion. When [¹⁸F]-EF5 was injected into a rat followed by urine collection and analysis, we found no detectable metabolism to other radioactive compounds. Thus, [¹⁸F]-EF5 should be well suited for use as a non-invasive hypoxia marker with detection using positron emission tomography (PET).

View all citing articles on Scopus

View full text

Radiolabeled hypoxic cell sensitizers: Tracers for assessment of ischemia

Abstract

Int. J. Radiation Oncol. Biol. Phys.

Int. J. Appl. Radiat. Isot.

Biochem. Pharm.

Int. J. Radiation Oncol. Biol. Phys.

Int. J. Nucl. Med. Biol.

Cancer Treat. Rev.

Oncology Biol. Phys.

Int. J. Appl. Rad. Isotop.

Exp. Neurol.

Brain Res.

Radiation Oncology Biol. Phys.

Progr. Brain Res.

N. Engl. J. Med.

Br. J. Cancer

Cancer

Brit. J. Radiol.

Brit. J. Cancer

Radiat. Res.

Brit. J. Radiol.

Lancet

Brit. J. Cancer

Cell Tissue Kinet.

Cancer Res

Radiol.

Am. J. Roentgenol.

Brit. J. Cancer

Brit. J. Radiol.

Cancer Res.

Rad. Res.

Brit. J. Cancer

Radiol.

Br. Med. Bull.

Brit. J. Cancer

Brit. J. Cancer

radiat. Res.

N. Engl. J. Med.

Cancer

Cancer Res.